PBLS Stock: Price, Earnings History and SEC Filings
Parabilis Medicines, Inc. (PBLS) last traded at $28.32, down 1.32% on the latest session and down 12.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.13 against an analyst estimate of $-0.16, a miss of 1231.3%.
$28.32 -1.32%
1 month-12.29%
52-week high$42.49
52-week low$22.66
Volume813,967
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PBLS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-2.13 | $-0.16 | -1231.25% |
PBLS beat the analyst EPS estimate in 0 of its last 1 reported quarters. Source: Nasdaq.
Latest SEC filings for PBLS
SEC filing data is not available right now. You can search for PBLS on SEC EDGAR.
PBLS news
- Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027Oct 24, 2026 · marketbeat.com
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid TumorsOct 24, 2026 · finance.yahoo.com
- Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial UpdatesOct 20, 2026 · finance.yahoo.com
- Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial ExpandsOct 20, 2026 · finance.yahoo.com
- What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?Oct 20, 2026 · finance.yahoo.com
- Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor DrugOct 19, 2026 · tikr.com
- Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026Oct 19, 2026 · finance.yahoo.com
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. (PBLS) is a US-listed public company on Nasdaq.